Menu
  • Join
  • Login
  • Contact
 

Search abstracts


The medicines innovation landscape according to the 2015 FDA and EMA approvals

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: DELGADO-CHARRO, M Begona (University of Bath, Pharmacy and Pharmacology, Bath, United Kingdom)
  • Co-author(s): M Begona Delgado-Charro: Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
    Chloe Atkinson: Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
    Sara Shasha’h: Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
    Louise Johson: Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
    Agnes Wong: Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
  • Abstract:

    Backgrounds

    Faster patient access to innovative medicines requires progress in drug discovery and development processes as well as in regulatory and HTA assessment.

    Aims

    This project explored the use the EMA and FDA public assessment reports as tools to identify key innovative trends in regulatory approvals.

    Methods

    The “2015 approvals” data set was

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses